These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36675950)

  • 1. The Allosteric Antagonist of the Sigma-2 Receptors-Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer's Disease: A Scoping Systematic Review.
    Rasheed A; Zaheer AB; Munawwar A; Sarfraz Z; Sarfraz A; Robles-Velasco K; Cherrez-Ojeda I
    Life (Basel); 2022 Dec; 13(1):. PubMed ID: 36675950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT1812, a Small Molecule Sigma-2 Receptor Antagonist for Alzheimer's Disease Treatment: A Systematic Review of Available Clinical Data.
    Thitilertdecha P; Brimson JM
    J Alzheimers Dis; 2024; 101(s1):S115-S128. PubMed ID: 39422939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.
    Grundman M; Morgan R; Lickliter JD; Schneider LS; DeKosky S; Izzo NJ; Guttendorf R; Higgin M; Pribyl J; Mozzoni K; Safferstein H; Catalano SM
    Alzheimers Dement (N Y); 2019; 5():20-26. PubMed ID: 30723776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist.
    Kaur G; Dar ZA; Bajpai A; Singh R; Bansal R
    Clin Ther; 2024 Sep; ():. PubMed ID: 39289058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
    Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease.
    Lizama BN; Williams C; North HA; Pandey K; Duong D; Di Caro V; Mecca AP; Blennow K; Zetterberg H; Levey AI; Grundman M; van Dyck CH; Caggiano AO; Seyfried NT; Hamby ME
    Alzheimers Dement; 2024 Oct; 20(10):6860-6880. PubMed ID: 39166791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 fatty acids for the treatment of dementia.
    Burckhardt M; Herke M; Wustmann T; Watzke S; Langer G; Fink A
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009002. PubMed ID: 27063583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease and clinical trials.
    Paul D; Agrawal R; Singh S
    J Basic Clin Physiol Pharmacol; 2024 Jan; 35(1-2):31-44. PubMed ID: 38491747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease.
    Rishton GM; Look GC; Ni ZJ; Zhang J; Wang Y; Huang Y; Wu X; Izzo NJ; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Catalano SM
    ACS Med Chem Lett; 2021 Sep; 12(9):1389-1395. PubMed ID: 34531947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of atorvastatin for the treatment of Alzheimer's disease.
    Sun Y; Wang G; Pan Z; Chen S
    Neural Regen Res; 2012 Jun; 7(17):1344-51. PubMed ID: 25657666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Older patients are still under-represented in clinical trials of Alzheimer's disease.
    Banzi R; Camaioni P; Tettamanti M; Bertele' V; Lucca U
    Alzheimers Res Ther; 2016 Aug; 8():32. PubMed ID: 27520290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.